RT Journal Article
SR Electronic
T1 The National Psychiatric Morbidity Survey of Pakistan (2022): Prevalence, socio-demographic and disability correlates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.08.24310056
DO 10.1101/2024.07.08.24310056
A1 Rahman, R
A1 Sheehan, D
A1 Javed, A
A1 Ahmad, SH
A1 Shafiq, K
A1 Kanwal, U
A1 Afridi, MI
A1 Nizami, AT
A1 Rasool, G
A1 Taj, R
A1 Ansari, M
A1 Naim, M
A1 Farooq, S
A1 Memon, A
A1 Karim, MS
A1 Hana, Y
A1 Ayub, M.
YR 2024
UL http://medrxiv.org/content/early/2024/07/08/2024.07.08.24310056.abstract
AB Background National psychiatric morbidity surveys have shown a wide range of prevalence of psychiatric disorders across different countries. Pakistan with its sociocultural and ethnic diversity, has the fifth largest population in the world. There was no prior high-quality nationally representative data on the prevalence of psychiatric disorders and their socio-demographic correlates for Pakistan. To fill this gap in the planning of mental health services, the Pakistan Psychiatric Society conducted the National Psychiatric Morbidity Survey (NPMS) of Pakistan, in the years 2019-2022.Aim To estimate the prevalence and socio-demographic correlates of psychiatric morbidity in a representative sample of Pakistan.Methods The cross-sectional NPMS collected data from the four provinces of Pakistan. After selection through a three-stage, stratified, random cluster sampling technique we interviewed 17,773 adults above the age of 18. We used the MINI International Neuropsychiatric Interview (MINI Version 7.0.2) to evaluate psychiatric morbidity. Current and lifetime precise and weighted prevalence is reported according to ICD-10 (International Classification of Disease-10th version). We used multivariate logistic regression to investigate the association between the risk of psychiatric illness and sociodemographic variables. National Bio-ethic Committee of Pakistan granted approval of survey.Results The lifetime and current weighted prevalence of all psychiatric disorder is 37.91% (95% Confidence Interval (CI) =37.22-38.59) and 32.28% (95% CI=31.62-32.94) respectively. The weighted prevalence of common psychiatric disorders in Pakistan included Mood Disorders (F30-F39; 19.62%), Neurotic and Stress-related Disorders (F40 F48; 24.81%), Psychotic Disorders (F20-F29; 4.52%) and Mental and Behavioural Problems due to Psychoactive Substance use (F10-F19; 0.85%). The psychiatric disorders had an association with age, female gender, urban living, lower income and being divorced. Among participants, 6.17% acknowledged suicidality in the past month, while 1.05% acknowledged a lifetime suicide attempt.Conclusion The NPMS is the first nationally representative study of psychiatric morbidities in Pakistan. The data from this survey can be utilized for designing and implementing mental health services and support programmes in the country.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://pakistanpsychiatricsurvey.org/ Funding StatementThis study is funded through a grant by Pakistan Psychiatric Society.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The approval of NPMS was given by the National Bioethics Committee of Pakistan (letter No. 4-87/NBC-268/171/370, dated November 11, 2017) as well as the institutional review board of the Dow University of Health Sciences.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors